Please Subscribe to get a daily link to Pat's blog via email

Subscribe!

Your privacy is important to us. We will never spam you and keep your personal data secure.

Evidence Shows Zometa Features Anti-Myeloma Benefit For Patients. But How About Another Often Used Bisphosphonate, Aredia?

Home/Evidence Shows Zometa Features Anti-Myeloma Benefit For Patients. But How About Another Often Used Bisphosphonate, Aredia?

Evidence Shows Zometa Features Anti-Myeloma Benefit For Patients. But How About Another Often Used Bisphosphonate, Aredia?

This article from WebMD speaks for itself:

Bone Drug May Help Treat Multiple Myeloma

Study Shows Zometa May Improve Survival for Patients With Multiple Myeloma
By Salynn BoylesWebMD Health News

Reviewed by Laura J. Martin, MD Dec. 3, 2010 — Adding the intravenous bone drug Zometa to chemotherapy improves survival in patients with the blood cancer multiple myeloma, new research from the U.K. shows.

Patients treated with Zometa (zoledronic acid) lived an average of five and a half months longer than patients taking clodronic acid, an oral bone drug that is not used in the U.S.

Zometa and other drugs in the class known as bisphosphonates are also used in the treatment of breast cancer with bone involvement and other solid tumors that have spread to the bone.

The study is the first to show a survival benefit for a bisphosphonate in multiple myeloma patients, and its lead author says it should be considered the bone drug of choice in those with the disease.

But a multiple myeloma specialist who spoke to WebMD is not so sure. S. Vincent Rajkumar, MD, of the Mayo Clinic in Rochester, Minn., says the intravenous bisphosphonate Aredia (pamidronate), which is also widely use to treat the cancer in the U.S., may be just as effective.

“This study confirms the value of giving an IV bisphosphonate monthly to patients with myeloma-related bone disease, which is what oncologists in the U.S. have been doing,” he says. “We now know there is a survival benefit with Zometa. Since Aredia wasn’t studied, we don’t know if the same benefit exists with this drug.”

Here is a link to the rest of the article:  Zometa May Improve Survival for Patients,  along with an additional link to another article which discusses yesterday’s Zometa data from MedPageToday.com: 

ASH: Bone Drug Extends Life in Multiple Myeloma.

You will be reading a lot more about this.  I will add comments later in the week.
Feel good and keep smiling!  Pat